FY2025 EPS Estimates for Exelixis Lifted by William Blair

Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at William Blair raised their FY2025 EPS estimates for Exelixis in a note issued to investors on Sunday, January 12th. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings of $1.69 per share for the year, up from their prior forecast of $1.44. The consensus estimate for Exelixis’ current full-year earnings is $1.70 per share.

A number of other analysts have also issued reports on the company. Morgan Stanley raised their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, October 11th. Guggenheim raised their target price on shares of Exelixis from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. TD Cowen increased their price target on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Finally, JMP Securities boosted their price objective on shares of Exelixis from $34.00 to $41.00 and gave the company a “market outperform” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.50.

Exelixis Stock Down 1.9 %

Shares of NASDAQ:EXEL opened at $36.55 on Wednesday. The company has a market cap of $10.44 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.87 and a beta of 0.53. The business has a fifty day simple moving average of $34.95 and a 200-day simple moving average of $29.14. Exelixis has a 52 week low of $20.01 and a 52 week high of $37.59.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The firm had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the previous year, the company earned $0.10 EPS. Exelixis’s revenue for the quarter was up 14.3% on a year-over-year basis.

Institutional Investors Weigh In On Exelixis

A number of large investors have recently added to or reduced their stakes in EXEL. Los Angeles Capital Management LLC boosted its position in Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Exelixis in the third quarter worth about $14,979,000. Farallon Capital Management LLC boosted its holdings in Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after purchasing an additional 424,000 shares during the last quarter. AQR Capital Management LLC grew its stake in Exelixis by 12.7% during the 2nd quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock valued at $73,425,000 after purchasing an additional 370,199 shares in the last quarter. Finally, Burney Co. purchased a new stake in Exelixis during the 4th quarter worth approximately $12,267,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total value of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at $15,666,873. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $28.39, for a total transaction of $709,750.00. Following the transaction, the executive vice president now directly owns 580,325 shares in the company, valued at approximately $16,475,426.75. The trade was a 4.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 314,736 shares of company stock valued at $10,849,110 over the last quarter. Company insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.